Abbott Laboratories’ stock pulled back sharply in January 2026 on broad market volatility rather than any company-specific weakness, returning its valuation to levels last seen in mid-2024. Institutional commentary highlights that the share decline has restored the stock’s dividend yield to approximately 2.3%, up from 1.8% at the start of the year, and trimmed the price-to-earnings ratio to below 29. Long-term investors note that free cash flow exceeded $6 billion over the past four quarters and that the company has authorized a new $5 billion share repurchase program, underscoring management’s commitment to capital return in a lower-valued environment.

In its fourth quarter report, Abbott delivered adjusted earnings per share of $1.50, matching consensus estimates, and generated revenues of $11.46 billion, up 4.4% year-over-year but missing street expectations by roughly 3%. The Diagnostics and Nutrition segments underperformed, with Nutrition revenues down 8%–9% due to persistent headwinds in emerging-market demand, yet the Medical Devices division grew sales by 12% on strength in vascular and neuromodulation products. The company expanded its adjusted operating margin by 60 basis points to 23.5% and raised its quarterly dividend by 7% to $0.63 per share, marking its 51st consecutive year of payout growth.

Twenty-two brokerages covering Abbott maintain an average recommendation of Moderate Buy, with seventeen buy ratings and two strong buys, according to Marketbeat. Analysts have trimmed their 12-month price targets following the earnings report, with the consensus target now standing near the low 140s, down from mid-150s earlier in January. Despite downward revisions by firms such as Citigroup, Sanford C. Bernstein and Goldman Sachs, most maintain outperform or buy ratings, citing the company’s projected 6.5%–7.5% sales growth for fiscal 2026 and management’s guidance for adjusted EPS of $5.55–$5.80 as evidence of continued growth potential and margin resilience.